Shanghai Yinnuo Pharmaceutical Technology
Peptide therapeutics
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorProtein / enzyme therapeutic | ObesityType 2 Diabetes |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
29 May 2026Topline resultefsubaglutide alfaPhase IIb portion of ENLIGHT (NCT06921486) met its primary endpoint
Financial reports
No financial reports recorded.